211 related articles for article (PubMed ID: 31119377)
1. Phosphodiesterase 10A levels are related to striatal function in schizophrenia: a combined positron emission tomography and functional magnetic resonance imaging study.
Persson J; Szalisznyó K; Antoni G; Wall A; Fällmar D; Zora H; Bodén R
Eur Arch Psychiatry Clin Neurosci; 2020 Jun; 270(4):451-459. PubMed ID: 31119377
[TBL] [Abstract][Full Text] [Related]
2. Striatal phosphodiesterase 10A and medial prefrontal cortical thickness in patients with schizophrenia: a PET and MRI study.
Bodén R; Persson J; Wall A; Lubberink M; Ekselius L; Larsson EM; Antoni G
Transl Psychiatry; 2017 Mar; 7(3):e1050. PubMed ID: 28267149
[TBL] [Abstract][Full Text] [Related]
3. Characterization of [
Yang KC; Stepanov V; Amini N; Martinsson S; Takano A; Nielsen J; Bundgaard C; Bang-Andersen B; Grimwood S; Halldin C; Farde L; Finnema SJ
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):308-320. PubMed ID: 27817159
[TBL] [Abstract][Full Text] [Related]
4. Positron Emission Tomography Assessments of Phosphodiesterase 10A in Patients With Schizophrenia.
Kubota M; Takahata K; Matsuoka K; Sano Y; Yamamoto Y; Tagai K; Tarumi R; Suzuki H; Kurose S; Nakajima S; Shiwaku H; Seki C; Kawamura K; Zhang MR; Takahashi H; Takado Y; Higuchi M
Schizophr Bull; 2023 May; 49(3):688-696. PubMed ID: 36458958
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase-10A Inverse Changes in Striatopallidal and Striatoentopeduncular Pathways of a Transgenic Mouse Model of
D'Angelo V; Castelli V; Giorgi M; Cardarelli S; Saverioni I; Palumbo F; Bonsi P; Pisani A; Giampà C; Sorge R; Biagioni S; Fusco FR; Sancesario G
J Neurosci; 2017 Feb; 37(8):2112-2124. PubMed ID: 28115486
[TBL] [Abstract][Full Text] [Related]
6. Effects of a novel phosphodiesterase 10A inhibitor in non-human primates: A therapeutic approach for schizophrenia with improved side effect profile.
Masilamoni GJ; Uthayathas S; Koenig G; Leventhal L; Papa SM
Neuropharmacology; 2016 Nov; 110(Pt A):449-457. PubMed ID: 27539962
[TBL] [Abstract][Full Text] [Related]
7. Patterns of age related changes for phosphodiesterase type-10A in comparison with dopamine D
Fazio P; Schain M; Mrzljak L; Amini N; Nag S; Al-Tawil N; Fitzer-Attas CJ; Bronzova J; Landwehrmeyer B; Sampaio C; Halldin C; Varrone A
Neuroimage; 2017 May; 152():330-339. PubMed ID: 28254508
[TBL] [Abstract][Full Text] [Related]
8. Discovery and development of 11C-Lu AE92686 as a radioligand for PET imaging of phosphodiesterase10A in the brain.
Kehler J; Kilburn JP; Estrada S; Christensen SR; Wall A; Thibblin A; Lubberink M; Bundgaard C; Brennum LT; Steiniger-Brach B; Christoffersen CT; Timmermann S; Kreilgaard M; Antoni G; Bang-Andersen B; Nielsen J
J Nucl Med; 2014 Sep; 55(9):1513-8. PubMed ID: 24994928
[TBL] [Abstract][Full Text] [Related]
9. Quantification of 18F-JNJ-42259152, a novel phosphodiesterase 10A PET tracer: kinetic modeling and test-retest study in human brain.
Van Laere K; Ahmad RU; Hudyana H; Dubois K; Schmidt ME; Celen S; Bormans G; Koole M
J Nucl Med; 2013 Aug; 54(8):1285-93. PubMed ID: 23843566
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase 10A controls D1-mediated facilitation of GABA release from striato-nigral projections under normal and dopamine-depleted conditions.
Mango D; Bonito-Oliva A; Ledonne A; Nisticò R; Castelli V; Giorgi M; Sancesario G; Fisone G; Berretta N; Mercuri NB
Neuropharmacology; 2014 Jan; 76 Pt A():127-36. PubMed ID: 23973317
[TBL] [Abstract][Full Text] [Related]
11. PDE10A and PDE10A-dependent cAMP catabolism are dysregulated oppositely in striatum and nucleus accumbens after lesion of midbrain dopamine neurons in rat: a key step in parkinsonism physiopathology.
Giorgi M; Melchiorri G; Nuccetelli V; D'Angelo V; Martorana A; Sorge R; Castelli V; Bernardi G; Sancesario G
Neurobiol Dis; 2011 Jul; 43(1):293-303. PubMed ID: 21515371
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase 10A in Schizophrenia: A PET Study Using [(11)C]IMA107.
Marques TR; Natesan S; Niccolini F; Politis M; Gunn RN; Searle GE; Howes O; Rabiner EA; Kapur S
Am J Psychiatry; 2016 Jul; 173(7):714-21. PubMed ID: 26892941
[TBL] [Abstract][Full Text] [Related]
13. Cognitive impairment in schizophrenia is associated with prefrontal-striatal functional hypoconnectivity and striatal dopaminergic abnormalities.
Yang KC; Yang BH; Liu MN; Liou YJ; Chou YH
J Psychopharmacol; 2024 Jun; 38(6):515-525. PubMed ID: 38853592
[TBL] [Abstract][Full Text] [Related]
14. Translational Development Strategies for TAK-063, a Phosphodiesterase 10A Inhibitor.
Macek TA; Suzuki K; Asin K; Kimura H
Int J Neuropsychopharmacol; 2020 Nov; 23(8):524-532. PubMed ID: 32598478
[TBL] [Abstract][Full Text] [Related]
15. Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease.
Niccolini F; Foltynie T; Reis Marques T; Muhlert N; Tziortzi AC; Searle GE; Natesan S; Kapur S; Rabiner EA; Gunn RN; Piccini P; Politis M
Brain; 2015 Oct; 138(Pt 10):3003-15. PubMed ID: 26210536
[TBL] [Abstract][Full Text] [Related]
16. PDE10A and ADCY5 mutations linked to molecular and microstructural basal ganglia pathology.
Niccolini F; Mencacci NE; Yousaf T; Rabiner EA; Salpietro V; Pagano G; Balint B; Efthymiou S; Houlden H; Gunn RN; Wood N; Bhatia KP; Politis M
Mov Disord; 2018 Dec; 33(12):1961-1965. PubMed ID: 30345538
[TBL] [Abstract][Full Text] [Related]
17. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey.
Smith SM; Uslaner JM; Cox CD; Huszar SL; Cannon CE; Vardigan JD; Eddins D; Toolan DM; Kandebo M; Yao L; Raheem IT; Schreier JD; Breslin MJ; Coleman PJ; Renger JJ
Neuropharmacology; 2013 Jan; 64():215-23. PubMed ID: 22750078
[TBL] [Abstract][Full Text] [Related]
18. Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease.
Niccolini F; Haider S; Reis Marques T; Muhlert N; Tziortzi AC; Searle GE; Natesan S; Piccini P; Kapur S; Rabiner EA; Gunn RN; Tabrizi SJ; Politis M
Brain; 2015 Oct; 138(Pt 10):3016-29. PubMed ID: 26198591
[TBL] [Abstract][Full Text] [Related]
19. In vitro phosphodiesterase 10A (PDE10A) binding in whole hemisphere human brain using the PET radioligand [
Svedberg MM; Varnäs K; Varrone A; Mitsios N; Mulder J; Gulyás B; Beaumont V; Munoz-Sanjuan I; Zaleska MM; Schmidt CJ; Halldin C; Mrzljak L
Brain Res; 2019 May; 1711():140-145. PubMed ID: 30664847
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia.
Menniti FS; Chappie TA; Humphrey JM; Schmidt CJ
Curr Opin Investig Drugs; 2007 Jan; 8(1):54-9. PubMed ID: 17263185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
